Lakeside Holding, a US-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market has announced that Hupan Pharmaceutical has signed a Sales Agreement with Sinopharm Holding Hubei New Special Medicine Co., a subsidiary of Sinopharm Group, based in China.

The agreement, valued at approximately RMB 11.0 million (approximately $1.5 million), is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride. 

This agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services. These achievements reflect Hupan Pharmaceutical's expanding role as a reliable provider of pharmaceutical solutions in China.

"We are excited to strengthen our relationship with Sinopharm Group further, a leading global player in the healthcare industry," said Lan Su, COO of Lakeside Holding Limited. "This agreement demonstrates our capabilities in delivering high-quality pharmaceutical products, ensuring reliable supplies of essential medicines. We remain committed to broadening our portfolio and expanding our market reach, enhancing our role as a trusted pharmaceutical solutions provider."